Navigation Links
Popular drugs for common male health problems can affect their sexual health
Date:3/7/2011

A new study published in The Journal of Sexual Medicine reveals that, for the first time, 5a-reductase inhibitors commonly used to treat urinary problems in patients with benign prostatic hyperplasia (BPH) and found in popular medications to treat hair loss, can produce, persistent erectile dysfunction (ED), depression and loss of libido, even after the medication has been discontinued.

Researchers led by Abdulmaged M. Traish, MBA, PhD, of Boston University School of Medicine, examined data reported in various clinical studies from the available literature concerning the side effects of the 5 alpha reductase inhibitors, finasteride and dutasteride.

Prolonged adverse side effects on sexual function, such as ED, depression and diminished libido, were reported by a subset of men. Drug-related reduction in libido occurred in 4.2% and 1.8% of patients in the dutasteride and placebo groups, respectively. Reduced ejaculation and semen volume were also reported and in some patients, these drugs were associated with depression.

"For these reasons, patients and doctors are urged to discuss these issues openly and candidly and assess the risk benefit ratio prior to commencing therapy with 5a-reductase inhibitors" Dr. Traish notes.

Dr. Irwin Goldstein, editor-in-chief of The Journal of Sexual Medicine, has seen and evaluated numerous such patients. He further explained the importance of this study. "Young men are being prescribed 5 alpha reductase inhibitors as hair loss treatments that may negatively impact their sexual life, possibly for a prolonged time after stopping the medication. Older men with symptoms of lower urinary tract symptoms or fearful of prostate cancer, now have to deal with new onset sexual and mental health problems. The growing use of 5 alpha reductase inhibitors is causing concerns." Clearly more research is needed to better understand the basis for these drug-associated side effects but it is evident that 5 alpha reductase inhibitors prevent the synthesis of very critical central nervous system neurosteroids and lower a very important sex steroid hormone, dihydrotestosterone.


'/>"/>

Contact: Amy Molnar
healthnews@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Popular Bone Drugs Linked to Reduced Colon Cancer Risk
2. Bullying May Accompany Drive to Be Popular
3. Zebrafish popular with researchers
4. Tanning Beds Still Popular Despite Skin Cancer Risk
5. Popular Mechanics breakthrough awardees announced
6. Popular prostate cancer treatment associated with bone decay
7. New guideline finds no evidence for a popular back procedure
8. Expert Panel Links Popular Bone Drugs to Rare Fracture
9. Popular diabetes drugs associated with fractures in type 2 diabetic patients
10. New research finds no evidence that popular slimming supplements facilitate weight loss
11. Iceland -- Working on its Popularity for Travellers, Iceland ProTravel Supports Ad Campaign "Inspired by Iceland"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Elizabeth Murray has always loved ... join her with one on her shoulder and one on her arm. But she ... because of years of mitral valve prolapse. , The valves of the heart wouldn’t ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... university, has announced today the launch of its Associates and Bachelor's degrees in ... Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; Chairman and CEO of ...
(Date:5/3/2016)... ... May 03, 2016 , ... Boston Children’s Hospital today announced its new pediatric ... practice tricky or rare procedures in an environment that looks and feels real. , ... available to inventors and “hackers” to develop and test new devices or software platforms ...
(Date:5/3/2016)... ... May 03, 2016 , ... Park Cities Pet Sitter has ... adjacent to the 75204, 75205, 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and ... Midway Hollow, North Dallas, Plano, Preston Hollow and Park Cities areas of the Metroplex. ...
(Date:5/3/2016)... ... May 03, 2016 , ... Intrigma, the leading provider of ... is expanding its use of Intrigma’s cloud-based physician scheduling solution, Efficient Scheduler (a ... concept. The Portland, Oregon based health system conducted a one-year pilot of the ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
Breaking Medicine Technology: